The identification of exon 11 of PRLR led to the discovery of alternative spliced products and two novel short forms (SF) that can inhibit the long form (LF) of PRLr activity, which is relevant in physiological regulation and breast cancer. The gene discussed is PRLR; the disease is breast carcinoma.